Puracap Pharmaceuticals – Phase I/II ESA & Compliance Evaluation

Langan completed a Phase I Environmental Site Assessment and Limited Environmental Compliance review for Puracap Pharmaceuticals, LLC on a fast-track due diligence time period in response to a real estate transaction. The site consisted of a 180,000 SF pharmaceutical manufacturing facility located in Jamaica, New York. Three recognized environmental conditions (RECs) were identified by Langan during the Phase I ESA and further investigated during expedited Phase II ESA activities which included a geophysical survey and soil, soil vapor, and groundwater sampling.